Moxonidina Eg (Moxonidine)

Moxonidine acts as a selective agonist at imidazoline I1 receptors in the brainstem. Activation of these receptors reduces sympathetic nervous system activity, leading to decreased peripheral vascular resistance and a modest reduction in arterial blood pressure.

The appropriate dose of Moxonidina Eg is determined by the prescribing clinician based on the patient’s medical condition, response to therapy, and any concomitant medications. Dosage adjustments are made according to clinical judgment.

Safety of moxonidine in pregnancy has not been established, and it is generally avoided unless the potential benefit justifies the risk. Information on excretion in breast milk is limited, so use while breastfeeding should be considered only if clearly needed.

To place an order, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Moxonidine belongs to the imidazoline I1 receptor agonist class, offering a modest blood‑pressure reduction with a lower incidence of reflex tachycardia compared with some centrally acting agents like clonidine. It is often used when patients need an additional agent beyond ACE inhibitors, ARBs, diuretics or calcium‑channel blockers.

Moxonidina Eg should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the tablets from moisture and direct sunlight to maintain stability throughout its shelf life.

Moxonidina Eg is taken orally, usually with or without food, as directed by the prescriber. The tablet should be swallowed whole with a glass of water and not chewed or crushed unless specifically instructed.

Serious adverse events, although rare, include severe hypotension, bradycardia, allergic reactions such as rash or anaphylaxis, and significant liver enzyme elevations. Patients should seek immediate medical attention if they experience symptoms like fainting, rapid heartbeat, or signs of an allergic reaction.

Moxonidina Eg is contraindicated in patients with known hypersensitivity to moxonidine or any excipients in the formulation. It should be used with caution, or avoided, in individuals with severe renal or hepatic impairment, uncontrolled heart failure, or those who are pregnant unless the benefit outweighs the risk.